Mechanism profiling of hepatotoxicity caused by oxidative stress using antioxidant response element reporter gene assay models and big data

Environmental Health Perspectives

Volumn 124, Issue 5, 2016, Pages 634-641

  Kim, Marlene Thai ^a   Huang, Ruili ^b   Sedykh, Alexander ^a,c   Wang, Wenyi ^a   Xia, Menghang ^b   Zhu, Hao ^a  

^a RUTGERS UNIVERSITY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c MULTICASE Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT RESPONSE ELEMENT BETA LACTAMASE REPORTER GENE ASSAY; ARTICLE; HIGH THROUGHPUT SCREENING; HUMAN; LIVER TOXICITY; OXIDATIVE STRESS; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; TOXICITY ASSAY; ANIMAL; ANTIOXIDANT RESPONSIVE ELEMENT; BIOASSAY; CELL LINE; COMPUTER SIMULATION; DANGEROUS GOODS; INFORMATION RETRIEVAL; LIVER; PHYSIOLOGY; PROCEDURES; REPORTER GENE; TOXICITY; TOXICITY TESTING;

DANGEROUS GOODS;

ANIMALS; ANTIOXIDANT RESPONSE ELEMENTS; BIOLOGICAL ASSAY; CELL LINE; COMPUTER SIMULATION; GENES, REPORTER; HAZARDOUS SUBSTANCES; HIGH-THROUGHPUT SCREENING ASSAYS; INFORMATION STORAGE AND RETRIEVAL; LIVER; OXIDATIVE STRESS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TOXICITY TESTS;

EID: 84964810430     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1509763     Document Type: Article

References (65)

1. Adler S, Basketter D, Creton S, Pelkonen O, van Benthem J, Zuang V, et al. 2011. Alternative (non- animal) methods for cosmetics testing: current status and future prospects—2010. Arch Toxicol 85:367–485.
2. Allen TEH, Goodman JM, Gutsell S, Russell PJ. 2014. Defining molecular initiating events in the adverse outcome pathway framework for risk assessment. Chem Res Toxicol 27:2100–2112.
3. Ankley GT, Bennett RS, Erickson RJ, Hoff DJ, Hornung MW, Johnson RD, et al. 2010. Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assess-ment. Environ Toxicol Chem 29:730–741.
4. Attene-Ramos MS, Miller N, Huang R, Michael S, Itkin M, Kavlock RJ, et al. 2013. The Tox21 robotic platform for the assessment of environmental chemicals—from vision to reality. Drug Discov Today 18:716–723.
5. Baell JB, Holloway GA. 2010. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 53:2719–2740.
6. Ben Hassine S, Arcangioli B. 2009. Tdp1 protects against oxidative DNA damage in non–dividing fission yeast. EMBO J 28:632–640.
7. Borduas N, da Silva G, Murphy JG, Abbatt JPD. 2015. Experimental and theoretical understanding of the gas phase oxidation of atmospheric amides with OH radicals: kinetics, products, and mechanisms. J Phys Chem A 119:4298–4308.
8. Breiman L. 2001. Random forests. Mach Learn 45:5–32.
9. Chabner BA, Bertino J, Cleary J, Ortiz T, Lane A, Supko JG, et al. 2011. Cytotoxic agents. In: Goodman & Gilman’s The Pharmacological Basis of Therapeutics (Brunton LL, Chabner BA, Knollmann BC, eds). 12th ed. New York:McGraw- Hill Companies, 1677–1730.
10. Chen M, Borlak J, Tong W. 2014. Predicting idiosyncratic drug-induced liver injury: some recent advances. Expert Rev Gastroenterol Hepatol 8:721–723.
11. Collins FS, Gray GM, Bucher JR. 2008. Toxicology. Transforming environmental health protection. Science 319:906–907.
12. Daniel WW. 2009. Biostatistics: A Foundation for Analysis in the Health Sciences. 9th ed. Hoboken, NJ:Wiley & Sons.
13. Davies DS, Thorgeirsson SS. 1971. Mechanism of hepatic drug oxidation and its relationship to indi-vidual differences in rates of oxidation in man. Ann NY Acad Sci 179:411–420.
14. Dix DJ, Houck KA, Martin MT, Richard AM, Setzer RW, Kavlock RJ. 2007. The ToxCast program for priori-tizing toxicity testing of environmental chemicals. Toxicol Sci 95:5–12.
15. Eaton DL, Gilbert SG. 2010. Principles of toxicology. In: Casarett & Doull’s Essentials of Toxicology (Klaassen CD, Watkins JB III, eds). 2nd ed. New York:McGraw-Hill Companies, 5–19.
16. Ekins S. 2014. Progress in computational toxicology. J Pharmacol Toxicol Methods 69:115–40.
17. Fielden MR, Brennan R, Gollub J. 2007. A gene expres-sion biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicals. Toxicol Sci 99:90–100.
18. Gaisford W. 1962. Fatality after oxyphenbutazone in Still’s disease. Br Med J 2:1517.
19. Golbraikh A, Shen M, Xiao Z, Xiao YD, Lee KH, Tropsha A. 2003. Rational selection of training and test sets for the development of validated QSAR models. J Comput Aided Mol Des 17:241–253.
20. Hartung T. 2009. Toxicology for the twenty-first century. Nature 460:208–212.
21. Huang MJ, Liaw YF. 1995. Clinical associations between thyroid and liver diseases. J Gastroenterol Hepatol 10:344–350.
22. Huang R, Southall N, Wang Y, Yasgar A, Shinn P, Jadhav A, et al. 2011. The NCGC pharmaceutical collection: a comprehensive resource of clini-cally approved drugs enabling repurposing and chemical genomics. Sci Transl Med 3:80ps16, doi:10.1126/scitranslmed.3001862.
23. Hybertson BM, Gao B, Bose SK, McCord JM. 2011. Oxidative stress in health and disease: the thera-peutic potential of Nrf2 activation. Mol Aspects Med 32:234–246.
24. Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, Yasgar A, et al. 2006. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci USA 103:11473–11478.
25. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, et al. 1997. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236:313–322.
26. Jameson JL, Weetman AP. 2012. Disorders of the thyroid gland. In: Harrison’s Principles of Internal Medicine (Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, eds). 18th ed. New York:McGraw-Hill Companies, 2911–2939.
27. Kensler TW, Wakabayashi N, Biswal S. 2007. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47:89–116.
28. Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H. 2014. Critical evaluation of human oral bioavailability for pharmaceutical drugs by using various cheminformatics approaches. Pharm Res 31:1002–1014.
29. Königer C, Wingert I, Marsmann M, Rösler C, Beck J, Nassal M. 2014. Involvement of the host DNA-repair enzyme TDP2 in formation of the cova-lently closed circular DNA persistence reservoir of hepatitis B viruses. Proc Natl Acad Sci USA 111:E4244–E4253.
30. Kwak MK, Wakabayashi N, Itoh K, Motohashi H, Yamamoto M, Kensler TW. 2003. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J Biol Chem 278:8135–8145.
31. Lafontan M, Girard J. 2008. Impact of visceral adipose tissue on liver metabolism. Part I: heterogeneity of adipose tissue and functional properties of visceral adipose tissue. Diabetes Metab 34(4 pt 1):317–327.
32. Low Y, Uehara T, Minowa Y, Yamada H, Ohno Y, Urushidani T, et al. 2011. Predicting drug-induced hepatotoxicity using QSAR and toxicogenomics approaches. Chem Res Toxicol 24:1251–1262.
33. Ma Q. 2013. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol 53:401–426.
34. MacDonald JS, Robertson RT. 2009. Toxicity testing in the 21st century: a view from the pharmaceutical industry. Toxicol Sci 110:40–46.
35. Malik R, Hodgson H. 2002. The relationship between the thyroid gland and the liver. QJM 95:559–569.
36. Mantena SK, King AL, Andringa KK, Eccleston HB, Bailey SM. 2008. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Free Radic Biol Med 44:1259–1272.
37. Moeller TA. 2010. From in vitro to in vivo. Drug Discovery & Development [news story]. Baltimore, MD; 06 August 2010. Available: http://www.dddmag.com/articles/2010/06/vitro-vivo [accessed 1 March 2015].
38. NCBI (National Center for Biotechnology Information). 2014. PubChem BioAssay Database. Available: http://www.ncbi.nlm.nih.gov/pcassay/ [accessed 27 February 2014].
39. NCBI. 2015. PubChem BioAssay Database; AID=651741. QHTS Assay for Small Molecule Agonists of the Antioxidant Response Element (ARE) Signaling Pathway. Available: https://pubchem.ncbi.nlm.nih.gov/bioassay/651741 [accessed 29 August 2015].
40. NRC (National Research Council, Committee on Toxicity Testing and Assessment of Environmental Agents). 2007. Toxicity Testing in the 21st Century: A Vision and a Strategy. Washington, DC:National Academies Press.
41. O’Brien PJ, Irwin W, Diaz D, Howard-Cofield E, Krejsa CM, Slaughter MR, et al. 2006. High concor-dance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell- based model using high content screening. Arch Toxicol 80:580–604.
42. Omura K. 2003. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemo-therapy: mutations in the DPD gene, and DPD inhibi-tory fluoropyrimidines. Int J Clin Oncol 8:132–138.
43. Porter NA, Caldwell SE, Mills KA. 1995. Mechanisms of free radical oxidation of unsaturated lipids. Lipids 30:277–290.
44. Pouliot JJ, Yao KC, Robertson CA, Nash HA. 1999. Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes. Science 286:552–555.
45. Sedykh A, Zhu H, Tang H, Zhang L, Richard A, Rusyn I, et al. 2011. Use of in vitro HTS-derived concentration– response data as biological descriptors improves the accuracy of QSAR models of in vivo toxicity. Environ Health Perspect 119:364–370, doi:10.1289/ehp.1002476.
46. Shuhendler AJ, Pu K, Cui L, Uetrecht JP, Rao J. 2014. Real-time imaging of oxidative and nitrosative stress in the liver of live animals for drug-toxicity testing. Nat Biotechnol 32:373–380.
47. Shukla SJ, Huang R, Simmons SO, Tice RR, Witt KL, Vanleer D, et al. 2012. Profiling environmental chemicals for activity in the antioxidant response element signaling pathway using a high throughput screening approach. Environ Health Perspect 120:1150–1156, doi:10.1289/ehp.1104709.
48. Sies H. 1997. Oxidative stress: oxidants and antioxi-dants. Exp Physiol 82:291–295.
49. Simmons SO, Fan CY, Yeoman K, Wakefield J, Ramabhadran R. 2011. Nrf2 oxidative stress induced by heavy metals is cell type dependent. Curr Chem Genomics 5:1–12.
50. Tai WW. 2012. Nonsteroidal anti-inflammatory drugs. In: Poisoning & Drug Overdose (Olson KR, ed). 6th ed. New York:McGraw-Hill Companies, 305–307.
51. Tice RR, Austin CP, Kavlock RJ, Bucher JR. 2013. Improving the human hazard characterization of chemicals: a Tox21 update. Environ Health Perspect 121:756–765, doi:10.1289/ehp.1205784.
52. Tontonoz P, Graves RA, Budavari AI, Erdjument- Bromage H, Lui M, Hu E, et al. 1994. Adipocyte- specific transcription factor ARF6 is a hetero dimeric complex of two nuclear hormone receptors, PPARγ and RXRα. Nucleic Acids Res 22:5628–5634.
53. Tropsha A, Golbraikh A. 2007. Predictive QSAR modeling workflow, model applicability domains, and virtual screening. Curr Pharm Des 13:3494–3504.
54. U.S. EPA (U.S. Environmental Protection Agency). 2012. Distributed Structure–Searchable Toxicity (DSSTox) Database. Available: http://www.epa.gov/ncct/dsstox/sdf_tox21s.html [accessed 2 October 2012].
55. Vapnik VN. 2000. The Nature of Statistical Learning Theory. New York:Springer.
56. Varma DR. 1987. Epidemiological and experimental studies on the effects of methyl isocyanate on the course of pregnancy. Environ Health Perspect 72:153–157.
57. Venugopal R, Jaiswal AK. 1998. Nrf2 and Nrf1 in asso-ciation with Jun proteins regulate antioxidant response element-mediated expression and coor-dinated induction of genes encoding detoxifying enzymes. Oncogene 17:3145–3156.
58. Wang Y, Suzek T, Zhang J, Wang J, He S, Cheng T, et al. 2014. PubChem BioAssay: 2014 update. Nucleic Acids Res 42(Database issue):D1075–D1082.
59. Willett P, Barnard JM, Downs GM. 1998. Chemical similarity searching. J Chem Inf Model 38:983–996.
60. Zhang D, Hannink M. 2003. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiqui-tination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol 23:8137–8151.
61. Zhang J, Hsieh JH, Zhu H. 2014. Profiling animal toxicants by automatically mining public bioassay data: a big data approach for computational toxicology. PLoS One 9:e99863, doi:10.1371/journal.pone.0099863.
62. Zheng W, Tropsha A. 2000. Novel variable selection quantitative structure—property relationship approach based on the k-nearest-neighbor principle. J Chem Inf Comput Sci 40:185–194.
63. Zhu H, Kim M, Zhang L, Sedykh A. 2013. Computers instead of cells: computational modeling of chemical toxicity. In: Reducing, Refining and Replacing the Use of Animals in Toxicity Testing (Allen D, Waters MD, eds). Cambridge, UK:Royal Society of Chemistry, 163–182.
64. Zhu H, Zhang J, Kim MT, Boison A, Sedykh A, Moran K. 2014. Big data in chemical toxicity research: the use of high-throughput screening assays to identify potential toxicants. Chem Res Toxicol 27:1643–1651.
65. Zhu X, Kruhlak NL. 2014. Construction and analysis of a human hepatotoxicity database suitable for QSAR modeling using post-market safety data. Toxicology 321:62–72.